Biostage, Inc. (NASDAQ:BSTG) issued its earnings results on Monday. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.03, MarketWatch Earnings reports.

Biostage (NASDAQ:BSTG) opened at 0.42 on Tuesday. The company’s market cap is $15.59 million. The stock has a 50 day moving average of $0.48 and a 200 day moving average of $0.39. Biostage has a one year low of $0.22 and a one year high of $1.42.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at

Separately, Maxim Group restated a “hold” rating on shares of Biostage in a report on Monday, August 7th.

An institutional investor recently raised its position in Biostage stock. Vanguard Group Inc. increased its stake in shares of Biostage, Inc. (NASDAQ:BSTG) by 4.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 773,820 shares of the biotechnology company’s stock after buying an additional 29,902 shares during the period. Vanguard Group Inc. owned about 2.08% of Biostage worth $319,000 at the end of the most recent quarter. Institutional investors own 6.99% of the company’s stock.

Biostage Company Profile

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

Earnings History for Biostage (NASDAQ:BSTG)

Receive News & Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.